Login to Your Account

Financings Roundup

Antibiotic Firm Cempra Hangs in After Price Cut on $50M IPO

By Trista Morrison
Staff Writer

Monday, February 6, 2012

If you were looking for a sign that post-J.P. Morgan optimism and a flurry of drug approvals might blow the biotech initial public offering (IPO) window open again – keep looking.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription